Do you include gemtuzumab ozogamicin for any of your newly diagnosed AML patients who are candidates for 7+3 induction chemotherapy?

Or do you consider addition of this agent in the re-induction setting for refractory disease?

Answer from: Medical Oncologist at Academic Institution

Yes, I regularly add gemtuzumab ozogamicin (3 mg/m2 IV days 1, 4 and 7) to 7+3 (daunorubicin dose should be 60 mg/m2 IV days 1-3) in newly diagnosed AML in the following patient groups based on the ALFA-0701 data (Castaigne, Lancet 2012): 1) Favorable/Intermediate-risk cytogenetics- subset anal...

Comments

Medical Oncologist at Texas Oncology
I'm curious why you recommend it if there is no OS...

Medical Oncologist at UNC Lineberger Comprehensive Cancer Center
The ALFA-0701 study (Randomized phase 3 trial of 7...

Medical Oncologist at Texas Oncology
Thank you.

Medical Oncologist at The Christ Hospital Network
Thanks for the details.

Please select the option that best describes you:

Do you include gemtuzumab ozogamicin for any of your newly diagnosed AML patients who are candidates for 7+3 induction chemotherapy?

Related Questions